MedPath

Study of Jianpi Huashi Decoction and Mesalazine on Ulcerative Colitis Patients with Spleen Deficiency and Damp-Heat Type

Phase 1
Recruiting
Conditions
icerative colitis
Registration Number
ITMCTR2000003714
Lead Sponsor
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of TCM
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. According to the diagnostic criteria of Western medicine for ulcerative colitis, the clinical severity is mild to moderate; the lesions include rectum, left colon or extensive colon; the clinical types are primary or chronic relapse;
2. TCM syndrome differentiation belongs to spleen deficiency damp heat type;
3. They are between 18 and 75 years old;
4. The patient voluntarily participated in the clinical trial and signed the informed consent.

Exclusion Criteria

1. Patients with chronic persistent, fulminant and severe ulcerative colitis.
2. Patients with infectious colitis such as bacillary dysentery, amebic dysentery, chronic schistosomiasis, intestinal tuberculosis, Crohn's disease, ischemic enteritis and radiation enteritis.
3. Patients have serious complications, such as local stenosis, intestinal perforation, intestinal obstruction, massive hemorrhage, toxic megacolon, colorectal cancer and so on.
4. Combined with heart, liver, kidney, hematopoietic system, endocrine system and other serious primary diseases and mental patients.
5. Pregnant or preparing pregnant women, lactating women, allergic constitution and allergic to this drug.
6. Those who have been treated with hormone therapy or other related drugs or are participating in other clinical trials.
7. Suspected or confirmed history of alcohol and drug abuse.
8. Those who do not cooperate with the treatment and cannot judge the curative effect.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
clinical efficacy rate;
Secondary Outcome Measures
NameTimeMethod
laboratory index;endoscopic response rate;mucosal healing rate;quality of life;TCM syndrome efficacy;clinical remission rate;emotion evaluation;
© Copyright 2025. All Rights Reserved by MedPath